Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BEIJING, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters

Related Keywords

Australia ,Germany ,Shanghai ,China ,United States ,Boston ,Massachusetts ,Beijing ,Heidelberg ,Baden Wüberg ,Chicago ,Illinois ,America ,Haimen Jiangsu ,Prnewswire Eucure Biopharma ,Biocytogen Eucure Biopharma ,Kostenloser Wertpapierhandel ,Eucure Biopharma ,Zimeng Zhang ,Vinod Ganju ,Biocytogen Pharmaceuticals Beijing Co Ltd ,Biocytogen Pharmaceuticals ,Project Integrum ,Eucure Biopharma Contacts ,Biocytogen ,Bucure ,Iopharma ,Present ,Linical ,Data ,Rom ,H003 ,Anti ,Cd40 ,H001 ,Tla ,Trials ,022 ,American ,Society ,Ncology ,Disco ,Nnual ,Meeting ,